Skip to main content
    X

    Xenon Pharmaceuticals Inc (XENE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $39.26
    -1.22 (-3.01%)

    Market Cap: $3.98B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xenon Pharmaceuticals Inc (XENE) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Xenon Pharmaceuticals (XENE) to earn -$4.57 per share in the fiscal year ending Dec 31, 2026, on revenue of $500000. Of 18 analysts, 17 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 94% of the ratings.

    RatingAnalystsShare
    Strong Buy316.7%
    Buy1477.8%
    Hold15.6%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    18

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 6560.0%.

    Fiscal year ending Dec 31, 2026
    -$4.57
    EPS consensus, revenue $500000
    Fiscal year ending Dec 31, 2027
    -$4.62
    EPS consensus, revenue $33.30M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.57-$4.73 to -$4.479$500000N/A10
    Dec 31, 2027-$4.62-$5.45 to -$1.9013$33.30MN/A12

    Quarterly Estimates

    The EPS consensus falls from -$1.17 for the quarter ending Dec 31, 2026 to -$1.21 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.17-$1.32 to -$0.8918$919020N/A16
    Mar 31, 2027-$1.21-$1.30 to -$1.025N/AN/A5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202730

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.63.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.57-$4.63-$4.63-$4.63-$4.63N/A
    Fiscal year ending Dec 31, 2027-$4.62-$4.70-$4.72-$4.80-$4.87N/A
    Quarter ending Mar 31, 2027-$1.21-$1.25-$1.25-$1.25-$1.25N/A

    Frequently Asked Questions About XENE

    What is the XENE stock forecast?

    Consensus analyst estimates put Xenon Pharmaceuticals's EPS at -$4.57 for the fiscal year ending Dec 31, 2026, on revenue of $500000. The consensus rating from 18 analysts is Buy.

    How do analysts rate XENE stock?

    Of 18 analysts covering Xenon Pharmaceuticals, 3 rate it Strong Buy, 14 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from XENE next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.57, with estimates from -$4.73 to -$4.47 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.62, with estimates from -$5.45 to -$1.90 from 13 analysts.

    What revenue do analysts expect from Xenon Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $500000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $33.30M.

    How many analysts cover XENE?

    18 analysts rate Xenon Pharmaceuticals stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.